Brief: Adc Therapeutics Announces FDA Approval Of ZYNLONTA In Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
23/04/2021 20:47
April 23 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS ANNOUNCES FDA APPROVAL OF ZYNLONTA™
(LONCASTUXIMAB TESIRINE-LPYL) IN RELAPSED OR REFRACTORY DIFFUSE
LARGE B-CELL LYMPHOMA
Source text for Eikon: urn:newsml:reuters.com:*:nBwb7yYXSa
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ADC Therapeutics SA
See all newsADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million